On the morning of June 12, 1979, in the pediatric operating room of University Hospitals of Cleveland, a four-and-one-half-month-old infant was the first human being to receive a percutaneous endoscopic gastrostomy. The procedure took less than fifteen minutes. There was no laparotomy, no general anesthesia, and no formal surgical recovery. The infant, who had inadequate oral intake from an underlying neurologic condition, was discharged shortly afterward.
Forty-seven years later, more than 200,000 of those procedures are performed annually in the United States. PEG, as the procedure is universally abbreviated, is the dominant modality for long-term enteral access. It is performed in every academic medical center, every community hospital, and most outpatient endoscopy suites in the developed world. Most clinicians under the age of fifty have never practiced in an environment where it was not available.
It is also the most recent fundamentally new architectural route for delivering nutrition to a body that cannot eat. Five such routes have been described in three thousand five hundred years of clinical practice. PEG is the fifth. Nothing has joined it.
This is the short version of how it came to be, who built it, and why nothing has come after.
What it replaced.
To understand PEG, it helps to understand what it ended.
Before 1979, the gold standard for long-term gastric enteral access was the open surgical gastrostomy. The procedure had been refined over the better part of a century, beginning with Charles-Émile Sédillot’s first attempted human gastrostomy at Strasbourg in 1849, in which the patient died. The technique that survived into the modern era was described by the American surgeon Martin Stamm in 1894, in a paper titled “Gastrostomy by a new method,” published in Medical News. The Stamm gastrostomy uses concentric purse-string sutures to create a serosa-lined channel from the stomach to the abdominal wall, and for the next eighty-five years it was the procedure clinicians turned to when a patient needed long-term enteral access.
It worked. It also required a laparotomy incision, general anesthesia, and a hospital stay measured in days. Mortality in older patient series ran twenty to thirty percent, the majority of which was attributable to the underlying disease rather than the procedure itself. The patients who needed gastrostomy were rarely well enough to tolerate a major operation. Many of them did not get one. The clinical literature of the 1960s and 1970s contains a recurring phrase: patients who would benefit from long-term enteral access but are not surgical candidates. It was the polite way of saying that the procedure that could feed them was the procedure that might kill them.
That was the gap a forty-three-year-old pediatric surgeon named Michael W.L. Gauderer was thinking about in the spring of 1979.
How it happened.
Gauderer had completed a pediatric surgery fellowship at the Children’s Hospital of Philadelphia from 1976 to 1978 and joined the faculty at Case Western Reserve University and Rainbow Babies and Children’s Hospital in Cleveland. His clinical practice included children with neurologic impairments who could not feed by mouth, and the calculation he kept doing in his head was that the surgical gastrostomy he was being asked to perform on these patients was a disproportionate operation for the problem at hand. The patients did not have abdominal surgical disease. They had a feeding problem. The laparotomy existed because it was the only way to get the stomach close enough to the abdominal wall to make an opening, and the general anesthesia existed because the laparotomy required it.
The conceptual question Gauderer started asking that spring was whether the stomach really needed to be brought to the abdominal wall surgically, or whether it could be brought there from the inside, by an endoscope. The pediatric flexible endoscopes available in 1979 were small enough to pass into a child’s stomach. They had a working channel through which a snare or a wire could be advanced. If the endoscope could push the gastric wall out toward the abdominal wall and a needle could be passed from the outside in, a wire could be retrieved, and a tube could be pulled back through the mouth, down the esophagus, and out through the abdominal wall. The procedure would be percutaneous. The procedure would be endoscopic. The procedure would not require a laparotomy.
Gauderer brought the idea to Jeffrey L. Ponsky, a general surgeon and surgical endoscopist at the same institution who had the technical fluency with flexible endoscopy that the procedure required. Ponsky worked through the technique with Gauderer in a series of laboratory experiments on dogs. The first human case was performed on the morning of June 12, 1979. The instrument used was a modified twelve-French de Pezzer mushroom-tipped catheter. The dilator was a tapered sixteen-gauge intravenous cannula. The traction was provided by a suture pulled retrograde through the mouth and out through the abdominal wall. The senior author and chief of pediatric surgery, Robert J. Izant Jr., supported the work and was the third name on the byline when the technique was published.
The first publication appeared in the Journal of Pediatric Surgery in December 1980, under the title “Gastrostomy without laparotomy: a percutaneous endoscopic technique.” The byline read Gauderer MWL, Ponsky JL, Izant RJ Jr. The paper has been cited several thousand times in the four decades since. It is generally regarded as the most-cited paper in the history of pediatric surgery.
What it changed.
The conceptual breakthrough was not the endoscope, which had existed for two decades. It was not the catheter, which was a standard catheter modified slightly. It was the sutureless approximation of a hollow viscus to the abdominal wall, which is what made the laparotomy unnecessary. By bringing the stomach toward the abdominal wall from the inside and using the catheter itself to maintain that approximation while the tract matured, Gauderer and Ponsky removed the operation from the procedure.
The downstream consequences were larger than the technical change suggests. PEG can be performed at the bedside in many institutions, and is more typically performed in an endoscopy suite under conscious sedation. It does not require an operating room. It does not require general anesthesia. The procedure itself usually takes less than fifteen minutes. The mortality of the procedure, in modern series, is well under one percent. Patients who would have been categorically excluded from a surgical gastrostomy because of cardiopulmonary risk are now routine PEG candidates. The economics changed at the same time. A procedure that had required a multi-day hospital stay became an outpatient procedure with same-day discharge in most cases.
Within ten years of the first publication, PEG had displaced surgical gastrostomy as the standard of care for long-term enteral access in the United States. The American Gastroenterological Association’s January 2025 Clinical Practice Update on Endoscopic Enteral Access cites more than 255,000 hospitalized patients per year requiring enteral nutrition support in the United States, the majority of which involves PEG or one of its derivatives: PEG with a jejunal extension, direct percutaneous endoscopic jejunostomy, low-profile button gastrostomy.
The procedure has variants. Percutaneous radiologic gastrostomy, first described in 1981, uses fluoroscopic guidance instead of an endoscope and is the preferred modality in patients who cannot tolerate the endoscopic transit. Percutaneous ultrasound gastrostomy is a more recent variant that uses ultrasound guidance for the abdominal wall puncture. These are real refinements, and they expand the population of patients in whom percutaneous gastric access is feasible. They do not, however, constitute new architectural routes. They are different ways to find the same anatomical pathway that Gauderer and Ponsky introduced in 1979.
What it has not changed.
Forty-seven years is a long time for a single procedure to remain the standard of care without successor. PEG has aged well, but it has not aged out of the limitations that any externalized feeding tube carries.
The literature on PEG complications is large and consistent. Tube dislodgement, particularly within the first few weeks before the gastrocutaneous tract is mature, is the most common reason for emergency department visits among PEG patients. Peristomal infection, granulation tissue, leakage around the tube, buried bumper syndrome, and the slow erosion of skin and tissue around the tube site are all well-described and have been described for decades. The patient population has not changed enough across forty years for the underlying complication rates to have changed materially.
The harder limitations are not medical. They are about what it means to live with a tube that emerges from the abdominal wall. Patients on long-term PEG describe a consistent set of experiences in the qualitative literature. The tube is visible to the patient and, in most clothing configurations, visible to anyone the patient is undressing in front of. Children with PEG are aware of being different from their classmates from the moment they understand what the tube is. Adolescents with PEG navigate dating, athletics, and intimacy around a device that does not let them forget it is there. Adults with PEG manage a similar set of social calibrations. The tube is also a fixed feature of the body. It is not removable for a special occasion. It is not removable when the patient wants a break. The geometry of the device (externalized, abdominal, fixed) is the geometry that defines the experience.
Forty-seven years of refinement has produced smaller tubes, lower-profile buttons, more durable materials, and better anti-reflux valves. None of these refinements changes the geometry. The tube emerges from the abdominal wall. It is visible. It is not removable by the patient at will. It is not reconcilable with normal eating in the way a contact lens is reconcilable with vision or a dental appliance is reconcilable with the mouth.
That is not a deficiency of PEG. It is a property of the route. Every external aperture in the body has the same property. The reason a sixth route has not appeared in forty-seven years is not that the need has not been recognized. The clinicians who care for these patients have always known. The reason is that the anatomy is unforgiving and the materials science required to do something genuinely different did not exist until recently.
Why this history matters now.
I run a medical device company that is attempting to add a sixth fundamentally new route to a list that has stood at five since 1979. I do not write this to claim a place on it. The list is held by a small group of clinicians whose work made the architecture of modern enteral nutrition possible. Hunter, Levin, Ryle, Stamm, Eiselsberg, Witzel, Gauderer, Ponsky, Izant, Dobbie, Hoffmeister. These are the names. Adding a sixth name to that list is the work of decades, not the work of a press release.
I write this because I think the context is worth being legible. Forty-seven years is a long time for a procedure to stand as the standard. PEG earned that position by being faster, safer, and substantially less expensive than the operation it replaced. Whatever comes after PEG will need to clear a comparable bar. The bar is not technical novelty. The bar is whether a clinician somewhere will choose the new option over PEG for a patient whose alternative has worked for almost half a century.
Alsteni Medical is in clinical development. The first-in-human feasibility trial of a prototype device, published in Nature’s Nutrition & Diabetes in 2020, documented zero serious adverse events across 334 cumulative device-days and a within-group weight loss signal of 2.4 kilograms in 14 days at p equals 0.008. Alsteni completed FDA Pre-Submission Q252869 in December 2025; FDA recommended an orogastric/oroenteric enteral feeding tube predicate under 21 CFR 876.5980 and indicated that limited 60–90 day clinical data focused on tolerability, nutrition delivery, and safety may support preparation of a future 510(k) submission. The 510(k) clinical study required by the FDA is in design with our regulatory advisors at MedTech Impact Partners. The Alsteni System is an investigational device. It is not FDA cleared or approved. The path is long. We are walking it.
Forty-seven years is a long time to wait for the next chapter. The work we are doing is intended to be that chapter, and the standard we are holding ourselves to is the standard that Gauderer, Ponsky, and Izant set on the morning of June 12, 1979.